Popular Pre-Market Trades in US Stocks
Opendoor Tech Series A - CW26, pre-market down 23.13%, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.
Top Gainers in Pre-Market US Stocks
Agape ATP pre-market up 52.78%. Based on recent news,
<ol>
<li>
On December 17, Agape ATP announced it will continue to focus on diversified businesses, covering health and wellness as well as sustainable green energy sectors, to provide sustainable shareholder value. This news boosted market confidence and drove the stock price up.
</li>
<li>
Recent financial reports show that Agape ATP's third-quarter revenue fell from $465,500 in the second quarter to $370,590, with a loss per share remaining at $0.01. Despite poor financial performance, the company's future development plans attracted investor attention.
</li>
<li>
Year-to-date, Agape ATP's stock price has dropped 92.24%, with a market capitalization of $4.55 million and a 52-week price range of $0.05 to $2.93. Although the overall trend is poor, recent business diversification plans have led to a short-term rebound in stock price. The health and wellness and green energy sectors have been active recently.
</li>
</ol>
DBV Technologies pre-market up 39.54%. Based on recent key news:
<ol>
<li>
On December 16, DBV Technologies announced that its drug VIASKIN for treating peanut allergy in children met its primary endpoint in Phase III trials, with the stock price soaring nearly 70%. Trial results showed that 46.6% of children responded to the drug within 12 months, compared to only 14.8% in the placebo group. The company plans to submit a biologics license application in the first half of 2026. Source: MT Newswires
</li>
<li>
On December 17, DBV Technologies' ABSA and BS warrants are now exercisable, potentially bringing the company up to €168.2 million in funding. The company expects to continue conducting open-label extension studies to assess long-term efficacy and safety. Source: RTT News
</li>
<li>
On December 15, Cantor Fitzgerald announced a target price of $42 per share for DBV Technologies. Source: RTT News The biotechnology sector has shown strong performance recently, with significant capital inflows.
</li>
</ol>
cbdMD, pre-market up 39.16%, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation

OPENL

Opendoor Tech Series A - CW26 pre-market down 23.13%; Agape ATP pre-market up 52.78%; DBV Technologies pre-market up 39.54%; cbdMD pre-market up 39.16%

Pre-market hot trades in US stocks: Opendoor Tech plummets 23.13% in pre-market, active trading sparks market volatility attention